To evaluate whether ABL-targeted gene editing can be used as an antileukemia therapy in the clinic, we infected the peripheral blood mononuclear cells (PBMCs) of CML patients with the ABL sgRNA_2-targeted CRISPR/Cas9 virus. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.